PolyPid regains European commercialization rights for D-PLEX₁₀₀
PolyPid (NASDAQ:PYPD) regained exclusive European commercialization rights for D-PLEX₁₀₀ after the company and ADVANZ PHARMA mutually agreed to terminate their 2022 licensing, distribution and supply agreement covering Europe.











